Procter & Gamble Health Ltd
₹ 6,286
-0.09%
20 Aug
- close price
About
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
Key Points
- Market Cap ₹ 10,434 Cr.
- Current Price ₹ 6,286
- High / Low ₹ 6,500 / 4,863
- Stock P/E 34.7
- Book Value ₹ 323
- Dividend Yield 1.99 %
- ROCE 47.8 %
- ROE 36.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.0%
- Company has been maintaining a healthy dividend payout of 67.5%
Cons
- Stock is trading at 19.4 times its book value
- The company has delivered a poor sales growth of 0.16% over past five years.
- Debtor days have increased from 39.5 to 56.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 16m | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,273 | |
809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 864 | |
Operating Profit | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 409 |
OPM % | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 32% |
20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 14 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
Depreciation | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 22 |
Profit before tax | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 400 |
Tax % | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | |
43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 301 | |
EPS in Rs | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 181.09 |
Dividend Payout % | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 0% |
3 Years: | -3% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 8% |
3 Years: | 10% |
TTM: | 43% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 6% |
3 Years: | 13% |
1 Year: | 17% |
Return on Equity | |
---|---|
10 Years: | 28% |
5 Years: | 27% |
3 Years: | 33% |
Last Year: | 36% |
Balance Sheet
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
Reserves | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | |
154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | |
Total Liabilities | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 |
110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | |
CWIP | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 |
Investments | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | |
Total Assets | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 |
Cash Flows
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | ||
11 | -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | ||
-17 | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | ||
Net Cash Flow | -1 | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 |
Ratios
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 |
Inventory Days | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 |
Days Payable | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 |
Cash Conversion Cycle | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 |
Working Capital Days | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 |
ROCE % | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% |
Documents
Announcements
-
Approval Of Promoter Reclassification Pursuant To Company''s Application Dated June 27, 2018
2d - Exchanges approved promoter reclassification; P&G Overseas India BV 51.82% promoter, public 48.18%; approval Aug 18, 2025.
-
Record Date For Annual General Meeting
6 Aug - Record date set as August 22, 2025, for AGM and dividend payment approval.
-
Business Responsibility and Sustainability Reporting (BRSR)
6 Aug - P&G Health's FY25 Business Responsibility & Sustainability Report filed, detailing ESG and governance practices.
-
Annual Report For The Financial Year 2024-25 And Notice Calling The 58Th Annual General Meeting Of The Company
6 Aug - 58th AGM notice for FY 2024-25 with financials, dividend, director reappointment, and auditor appointments.
-
Press Release For The Quarter Ended June 30, 2025
1 Aug - Q1 sales up 20% to ₹333 Cr; PAT ₹66 Cr vs ₹17 Cr last year for Procter & Gamble Health.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jun 2025Transcript PPT
-
Dec 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. [1]